NCT03645746View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 23, 2018

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Healthy Volunteer
Interventions
DRUG

REGN5069

REGN5069 will be administered by IV infusion or SC injection

DRUG

Placebo

Placebo-matching REGN5069

Trial Locations (1)

B-9000

Regeneron Research Facility, Ghent

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT03645746 - Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers | Biotech Hunter | Biotech Hunter